Breaking news

Isomorphic Labs Secures $600 Million To Revolutionize Drug Discovery With AI

by THEFUTURE.TEAM

April 7, 2025

Isomorphic Labs, the trailblazing AI-driven drug discovery startup, has successfully raised $600 million in its inaugural funding round. The Series A round, spearheaded by Thrive Capital, also saw continued backing from Alphabet’s Google Ventures, marking a significant milestone for the company.

Why This Matters

With AI rapidly becoming the core of innovation in nearly every tech sector, Isomorphic Labs is tapping into the booming intersection of artificial intelligence and pharmaceuticals. As demand for AI-powered solutions surges, particularly in drug development, this latest investment highlights the growing importance of AI in reshaping the life sciences industry.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The Backstory

Founded in 2021, Isomorphic Labs emerged from Google’s renowned AI research division, DeepMind. The company builds on DeepMind’s groundbreaking advancements, including the Nobel-winning “AlphaFold” model, which accurately predicts protein structures—critical to understanding diseases and developing new drugs. Isomorphic’s work represents the next frontier in AI-powered medicine.

Looking Ahead

The newly secured capital will fuel the company’s R&D ambitions and accelerate its talent acquisition. Founder and CEO Demis Hassabis, who also heads DeepMind, has ambitious plans. He aims for Isomorphic Labs to have AI-designed drugs entering clinical trials by the end of 2025—a timeline that underscores both the company’s potential and the immense promise of AI in revolutionizing drug discovery.

This $600 million funding round not only signals strong investor confidence but also cements Isomorphic Labs’ position at the forefront of the AI pharmaceutical revolution.

The Future Forbes Realty Global Properties

Cyprus: A Global Leader in Longevity and Healthcare Efficiency

by News Editor

May 9, 2025

In an eye-opening study conducted by renowned universities Brown and Harvard, Cyprus emerges as a global leader in longevity while maintaining low healthcare expenditures. The study, led by Cypriot professor Irini Papanikola, uncovers insightful data on Cyprus’s healthcare efficiency.

Key Findings

Published in the prestigious Journal of the American Medical Association Internal Medicine, the study highlights that Cyprus boasts some of the lowest mortality rates among high-income countries while ensuring affordable healthcare. This research has drawn significant attention, featured in media outlets across America and Europe.

Understanding Avoidable Mortality

The study examines avoidable mortality (deaths preventable through timely healthcare) across U.S. states and 40 high-income countries from 2009 to 2021. Remarkably, Cyprus presents some of the lowest avoidable mortality rates, showcasing the efficiency of its healthcare system even amid global challenges such as the COVID-19 pandemic.

Trends and Challenges

From 2009 to 2019, most high-income countries saw a decrease in avoidable mortality; however, this trend reversed for many, including Cyprus, during the pandemic years. The findings emphasize the critical role of robust public health systems in sustaining positive health outcomes.

The Path Forward

Despite the pandemic, Cyprus’s overall performance remains commendable. To achieve success, experts suggest addressing broader health determinants, focusing on preventive measures like road safety and mental health support through collaborative efforts.

Conclusion

Overall, Cyprus stands out as a beacon of healthcare efficiency, managing to reduce avoidable mortality with relatively low costs. This achievement underscores the country’s adeptness in providing high-quality healthcare, although continued research into population needs is vital for ongoing improvements.